News - Sanbio

Long COVID: Biomarker and Therapeutic Discovery

Written by Marketing Marketing | Oct 6, 2021 12:04:29 PM

SEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

COVID-19 symptoms can persist in an estimated 10% of patients long past recovering from the worst impacts of acute infection and testing negative for SARS-CoV-2. Inconsistencies in symptoms, patient phenotypes, and risk factors make it difficult to pinpoint the exact cause of Long COVID. In this issue of Cayman Currents, explore prominent theories of underlying pathophysiology, lessons from other post-viral syndromes, and Cayman’s products and services to accelerate Long COVID research.

Article:

DOWNLOAD THE INFOGRAPHIC

Request your physical copy here

SEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35